ArticleCureus2026
Asymptomatic Pembrolizumab-Associated Hypertriglyceridemia.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pembrolizumab is an immune checkpoint inhibitor that is widely used in the treatment of solid and hematological malignancies but is associated with immune-related adverse events. While the management of pembrolizumab-associated symptomatic hypertriglyceridemia associated with pancreatitis has been described, there is a lack of guidance for the treatment of pembrolizumab-associated asymptomatic hypertriglyceridemia. Here, we report a rare adverse event of pembrolizumab-associated asymptomatic hypertriglyceridemia after nine doses of pembrolizumab. The patient's lipid panel revealed grade 4 hypertriglyceridemia and hypercholesterolemia. Treatment was held, and the patient was treated with lipid-lowering therapies with improvement. Upon re-challenge, the grade 4 elevations returned while remaining asymptomatic. This case highlights a rare immune-related adverse event of asymptomatic hypertriglyceridemia. It underlines the importance of routine monitoring for adverse events with pembrolizumab, even in asymptomatic cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.